Peptides for weight loss: what works, what failed, and what your genes change

Every peptide with real weight-loss evidence is a prescription drug, and every "weight loss peptide" sold without one predates June 2021 and either failed its human trial or never ran one. Semaglutide (Wegovy) produced 14.9% mean body-weight loss over 68 weeks in a 1,961-person trial ¹. Tirzepatide (Zepbound) produced 20.9% over 72 weeks in 2,539 people ². Retatrutide, not yet approved, reached 24.2% over 48 weeks in phase 2 ⁴. This page walks the full evidence ladder, from those three down to the compounds vendors still sell on trials that never happened.

What are peptides for weight loss?

Peptides are short chains of amino acids, the building blocks of proteins. When people search for weight loss peptides, they nearly always mean the GLP-1 drug class. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating; it slows stomach emptying, sharpens insulin release, and tells the brain you are full. Semaglutide is a modified 31-amino-acid version of that hormone, engineered to last a week per injection instead of minutes. Tirzepatide adds a second gut-hormone signal, GIP (glucose-dependent insulinotropic polypeptide), and retatrutide adds a third, glucagon, which raises energy expenditure.

Semaglutide's approval for weight management in June 2021 ended the older weight-loss peptide market's scientific case ¹. Every compound still sold for weight loss by research-chemical vendors, AOD-9604, growth hormone secretagogues, MOTS-c, predates that approval, and none of them has a published human trial showing weight loss. The gap between the top and bottom of this category is the difference between a 2,539-person randomized trial and no trial at all.

Which peptides cause real weight loss? The evidence ladder

Every number in this table is a reported trial result, and mean results hide wide individual spread. The last row, lifestyle plus resistance training, is the comparator the rest of the ladder should be read against.

1

SemaglutideThe appetite regulator2

TirzepatideThe dual incretin3

RetatrutideThe one that works on three hormones at once4

CagrilintideThe amylin analog5

TesamorelinThe visceral-fat GHRH6

AOD-9604The fat metabolism peptide

Browse the full reference library →

Two rungs need context. Cagrilintide is a synthetic version of amylin, a fullness hormone released alongside insulin, and its future is as half of the CagriSema combination rather than a standalone drug ⁵. Tesamorelin is a synthetic version of the hormone that tells the pituitary to release growth hormone; its approval covers abnormal fat accumulation from HIV treatment, and prescribing it for general fat loss is off-label use its trials never tested ⁶.

Tirzepatide vs semaglutide: which wins?

For years the two drugs could only be compared across separate trials. SURMOUNT-5 settled it directly: 751 adults with obesity, randomized to one drug or the other for 72 weeks. Tirzepatide produced 20.2% mean weight loss; semaglutide produced 13.7% ³.

Practicalities decide more prescriptions than trial data. Both drugs are weekly injections from pens stored in the refrigerator. Without insurance, US list prices have run above $1,000 a month; both manufacturers now sell some doses through direct-to-patient programs for roughly a third to half of that, and prices shift often enough that any figure printed here will age. Trials escalated doses slowly over about 16 to 20 weeks because fast escalation drives the nausea that makes people quit ¹. If injections are new to you, start with peptides for beginners.

How much of the loss is muscle?

Lean tissue means muscle, bone, and organ mass, and losing it lowers your resting calorie burn, which works against keeping the weight off. A 2026 meta-analysis pooled 20 randomized trials covering 15,782 people and measured what share of lost weight was lean tissue under each approach ⁸:

Read the ordering carefully: lifestyle alone did worse than tirzepatide, and the best number on the board belongs to training. The pattern behind the so-called Ozempic face is this lean-tissue share at work. The drug trials themselves prescribed only a 500-calorie daily deficit and about 150 minutes a week of activity; the 17.5% figure comes from trials that added structured resistance training, and the meta-analysis suggests the training is what protects muscle ⁸. If body composition rather than scale weight is your goal, peptides for fat loss covers the recomposition angle and peptides for muscle growth covers the other half.

What happens when you stop?

The STEP 1 extension followed 327 participants for a year after their last semaglutide dose. They had lost a mean 17.3% of body weight by week 68; by week 120, they had regained 11.6 percentage points of it, leaving a net 5.6% loss ⁷.

GLP-1 drugs quiet the hunger signal while they are on board; they do not reset the weight the body defends. That regain curve is why clinical practice has shifted toward treating obesity as a chronic condition with indefinite maintenance dosing rather than a 12-month course, and it is a conversation to have with a clinician before the first injection, not after the last one ⁷.

The research-chemical tier: failed or never tested

AOD-9604 is the cautionary tale. It is a 16-amino-acid fragment of human growth hormone designed to trigger fat breakdown without growth hormone's effects on blood sugar. Its sponsor, Metabolic Pharmaceuticals, ran a 536-person phase 2b obesity program and announced roughly 2.6 kg of loss versus 0.8 kg on placebo at 12 weeks; the trial failed its primary endpoint, and the results never appeared in a peer-reviewed journal ¹³. As our AOD-9604 page puts it: "It is one of the few fat-loss peptides that got a proper human trial. It did not beat placebo, and development stopped." Two decades later, research-chemical vendors still sell AOD-9604 for weight loss on the strength of a trial that its own sponsor abandoned.

The rest of the tier is thinner still. Growth hormone secretagogue stacks such as CJC-1295 with ipamorelin raise growth hormone pulses, but no published human trial has tested them for weight loss. MOTS-c, a mitochondrial peptide, has mouse-stage metabolic evidence and is covered on its own page. None of these compounds is FDA-approved, and vials sold as research chemicals are manufactured outside any pharmaceutical standard, so the label's identity and dose are not verified by anyone.

Do collagen peptides help with weight loss?

No. Collagen peptides are hydrolyzed protein from animal connective tissue, food, not a signaling drug, and your gut digests them into amino acids like any other protein. The best randomized evidence collagen has is for joints: 10 g a day reduced activity-related joint pain over 24 weeks in a trial of 147 athletes ¹¹. No randomized trial has shown meaningful weight loss from collagen. As a protein source it can support fullness and muscle the way whey or chicken does, and that is the whole story.

Are peptides safe for weight loss?

For the approved drugs, safety is well mapped because the trials were large. Gut effects dominate: in STEP 1, 44.2% of semaglutide participants reported nausea, and 4.5% stopped the drug over gastrointestinal events ¹. Vomiting, diarrhea, and constipation are common during dose escalation and usually fade once the dose stabilizes. Rarer but serious: gallbladder disease (cholelithiasis, meaning gallstones, in 1.6% of Wegovy patients versus 0.7% on placebo across the weight-management trials, partly driven by rapid weight loss itself) and acute pancreatitis, reported in 4 semaglutide-treated patients in those trials, about 0.2 cases per 100 patient-years ¹².

For the research tier, the honest safety answer is that nobody knows, because the human trials that would surface side effects were never run. Absence of reported harms from a compound nobody has studied is not evidence of safety.

How do people get peptides for weight loss?

Semaglutide and tirzepatide are prescription drugs in the US, prescribed by clinicians including telehealth services, and that is the only route where the vial's contents are verified. FDA has warned specifically about unapproved and compounded GLP-1 products, citing dosing errors and counterfeit vials. Vendors also sell "research grade" semaglutide, tirzepatide, and retatrutide outside the pharmaceutical supply chain entirely. To be clear on status: those are unapproved new drugs, selling them for human use violates the Federal Food, Drug, and Cosmetic Act, and buying them means accepting an unverified molecule at an unverified dose, plus reconstitution and injection hygiene problems the prescription route never poses. This page explains the landscape; it is not a route map, and the decision belongs with a clinician.

If you are researching gray-market vendors anyway, our vendor comparison ranks them on third-party testing transparency. Disclosure: that comparison page carries affiliate links, and PeptidesDNA may earn a commission from purchases made through them.

Can your genes predict how much you'll lose?

Not yet, and anyone claiming otherwise is ahead of the data. What the data does show is that genes shape response at the population level. A genome-wide analysis of 4,571 adults found variants in ARRB1, the gene for beta-arrestin 1, a protein that shapes how the GLP-1 receptor signals after a drug binds it, associated with a larger blood-sugar response to GLP-1 drugs ¹⁰. That is response to the drug class measured on glucose, not on weight, but it is the first replicated evidence that GLP-1 drug response has a genetic component.

The most-discussed weight-related variant is GLP1R rs10305420, a change in the GLP-1 receptor gene itself. The largest human study, 285 adults on exenatide, tied the variant T allele to 1.27 kg less weight loss and a smaller drop in blood sugar ⁹. What evidence exists points toward weaker response in variant carriers, not stronger; no study has tested the variant with semaglutide, and consumer DNA chips do not all include a call for the position. FTO, the famous obesity-risk gene, raises the odds of gaining weight but has never been tested as a predictor of response to GLP-1 drugs.

The frame is association-only: a DNA report can show which GLP-1 and metabolism-related markers your file carries, and it cannot tell you which drug will work or how much you will lose. No genotype should change whether someone starts a GLP-1 drug or how a clinician adjusts the dose. For how genetic data fits a peptide decision at all, see the DNA decision framework.